Intranasal Drug Delivery Market Size, Share, Growth, and Industry Analysis, By Type (Multidose and Uni/Bidose), By Application (Personal Use and Hospital Use), and Regional Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

Intranasal Drug Delivery Market REPORT OVERVIEW

The global intranasal drug delivery market size was valued at USD 1.14 billion in 2023 and is projected to touch from USD 1.26 billion in 2024 to USD 2.90 billion by 2032, exhibiting a CAGR of 10.8% during the forecast period. North America is dominating the intranasal drug delivery market share in 2023.

The intranasal drug delivery market refers to the market for drugs that are administered through the nasal route. Intranasal drug delivery involves the delivery of medications through the nasal cavity, where they are absorbed directly into the bloodstream. This route of administration offers several advantages, such as rapid onset of action, avoidance of first-pass metabolism, and non-invasive delivery.

Moreover, intranasal drug delivery offers advantages over traditional oral or injectable routes. Nasal administration bypasses the gastrointestinal tract and avoids first-pass metabolism, which can enhance drug bioavailability and reduce the dose required for therapeutic effect. It also provides a needle-free alternative to injections, which can be beneficial for patients who have a fear of needles or require frequent medication administration.

COVID-19 Impact: Increased Focus on Respiratory Drug Delivery to Boost Demand Significantly

The COVID-19 pandemic has been unprecedented and staggering, with intranasal drug delivery market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The unforeseen rise in CAGR is attributable to the request’s growth and demand returning to pre-pandemic situations.

The COVID-19 had a life changing impact globally causing a strict lockdown and a halt to day-to-day activities in every industry with the limits imposed by the government. The pandemic has disrupted global supply chains, affecting the production and distribution of pharmaceutical products, including intranasal drug delivery systems. This disruption has led to challenges in maintaining a consistent supply of these devices, impacting the market. However, the market for intranasal drug delivery had an increase in demand.

The pandemic, caused by the novel coronavirus, primarily affects the respiratory system. This has led to an increased focus on the development and utilization of intranasal drug delivery systems for respiratory treatments, including vaccines, antivirals, and medications to manage symptoms.

Intranasal vaccine delivery has gained attention as a potential method for COVID-19 vaccination. Nasal vaccines have the advantage of eliciting both mucosal and systemic immune responses, potentially providing enhanced protection against respiratory viruses. Research and development efforts have been directed towards intranasal vaccine formulations, contributing to the growth of the intranasal drug delivery market. The intranasal drug delivery market is anticipated to grow following the pandemic

LATEST TRENDS

"Combination Therapies to Broaden Market Growth"

Intranasal drug delivery allows for the delivery of multiple drugs simultaneously or in a sequential manner. This has led to the exploration of combination therapies delivered intranasal for various indications. Combination therapies can provide synergistic effects, improved therapeutic outcomes, and simplified treatment regimens, which are particularly beneficial for chronic diseases and complex treatment protocols.

The market is witnessing the development of patient-friendly intranasal drug delivery devices. These devices focus on ease of use, comfort, and portability, catering to patient preferences for self-administration and convenience. For example, compact nasal spray devices with user-friendly features, such as dose counters and ergonomic designs, are gaining popularity.

In the intranasal drug delivery market, there is an increasing interest in repurposing drugs that are traditionally administered through other routes for intranasal delivery. This approach aims to improve therapeutic outcomes by utilizing the advantages of intranasal administration, such as faster onset of action, reduced systemic side effects, and improved patient compliance. These latest developments are anticipated to boost the intranasal drug delivery market growth

Intranasal Drug Delivery Market SEGMENTATION

• By Type

Based on type, the market is classified as multidose and uni/bidose.

Multidose as type holds the major share for the global market.

• By Application

Based on application, the market is bifurcated into personal use and hospital use.

Personal use as application holds the major share of the global market.

DRIVING FACTORS

"Advantages of Intranasal Route to Boost Market Share "

The intranasal route of drug delivery offers several advantages, such as rapid onset of action, avoidance of first-pass metabolism, non-invasive administration, and improved patient compliance. These advantages make intranasal drug delivery an attractive option for a wide range of therapeutic indications, including respiratory disorders, pain management, vaccines, and migraine, among others.

"Growing Prevalence of Chronic Diseases to Boost Market Size"

The increasing prevalence of chronic diseases, such as diabetes, respiratory disorders, and neurological conditions, is driving the demand for effective and convenient drug delivery methods. Intranasal drug delivery provides a targeted and efficient approach for delivering medications to treat these conditions, leading to better patient outcomes and improved disease management. These factors are anticipated to boost the intranasal drug delivery market share. These driving factors collectively contribute to the growth of the intranasal drug delivery market by expanding its applications, attracting investments, and increasing patient acceptance. The market is expected to continue expanding as research and development efforts progress and more therapeutic indications are targeted using intranasal drug delivery systems.

RESTRAINING FACTORS

"Limited Drug Compatibility to Hamper Market Share"

Not all drugs are suitable for intranasal delivery due to their chemical properties or low nasal permeability. Some drugs may be unstable or exhibit poor absorption through the nasal mucosa, which limits their suitability for intranasal administration. This constraint restricts the range of drugs that can be effectively delivered via the intranasal route. These factors are anticipated to hamper intranasal drug delivery market share. Intranasal drug delivery can sometimes cause nasal irritation, stinging, or adverse effects such as sneezing, rhinorrhea (runny nose), or nasal congestion. These local side effects can impact patient comfort and compliance, leading to potential limitations in the widespread adoption of intranasal drug delivery systems.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market
•  

"North America is a Major Shareholder for Intranasal Drug Delivery Market"

The market is global in nature, with various regions contributing to its growth and development. However, certain regions have shown significant activity and advancements in the field of intranasal drug delivery. North America has traditionally been a major player in the pharmaceutical industry and drug delivery technologies. The region has a robust healthcare infrastructure, a strong focus on research and development, and a favorable regulatory environment. These factors have contributed to the development and adoption of intranasal drug delivery systems in the region. Europe is the second major shareholder for the intranasal drug delivery market share.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Partnerships are being prioritized by key players in order to get a competitive advantage.

To stay ahead of the competition, prominent market players are collaborating by partnering with other companies. Many businesses are also investing in new product launches in order to diversify their product line. Mergers and acquisitions are other important strategy that players utilize to extend their product portfolio.

LIST OF TOP Intranasal Drug Delivery COMPANIES

• BD (Becton, Dickinson and Company) [U.S.]
• AptarGroup [U.S.]
• 3M [U.S.]
• Teleflex [U.S.]
• H&T Presspart [U.K.]
• Bespak [U.K.]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.